Plasma concentrations of metamizole metabolites in a clinical setting: evaluation of drug treatment via therapeutic drug monitoring (TDM)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034739

Enrollment

100

Registered

2024-08-16

Start date

2027-02-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R52.1 R52.0 R52.2 R52.9 R52

Interventions

Group 1: Adults of any gender with ability for informed consent and metamizole drug treatment. In this observational study, plasma concentrations of metamizole metabolites are determined via therapeut

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: No further specific criteria

Exclusion criteria

Exclusion criteria: Inability for informed consent

Design outcomes

Primary

Measure	Time frame
Plasma concentrations of the metabolites (MAA, AA, AAA, FAA) of metamizole (by LC-MS/MS)	—

Secondary

Measure	Time frame
Liver and renal function	—

Countries

Germany

Contacts

Public ContactDirk O. Stichtenoth

Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover

Stichtenoth.Dirk@mh-hannover.de+49 511 532 2820

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 27, 2026